Mr. Evert KÜppers
Chief Executive Officer (CEO)
Enzyme replacement therapies
United States of America
Prior to joining Oxyrane, Mr. Küppers was CEO of Swiss vaccine player Pevion Biotech AG. Previously, he was CEO of Munich-based Pieris AG, that he successfully restructured and refinanced, and Head of Business Development at IDEA AG for which he negotiated the largest German licensing deal in 2003 with Johnson & Johnson. Before joining the biotech industry, Mr. Küppers worked four years for BASF Pharma (now Abbott Laboratories) in International Operations (both at its German headquarters and Argentine subsidiary) and was a management consultant with the global pharmaceutical / health care team of AT Kearney in London, UK. Mr. Küppers holds an M.S. degree in Biomedical Sciences from Leiden University, The Netherlands, and an MBA from RSM/Erasmus University, The Netherlands.
Recombinant enzyme products, enzyme replacement therapies, lysosomal storage diseases (LSDs)